A Phase 3, Randomized, Open-Label, Multicenter Study of Amivantamab in Addition to Carboplatin and Pembrolizumab, Compared to Standard of Care Platinum and Pembrolizumab and 5-FU, in Participants With Treatment-Naïve Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
A Phase 3, Randomized, Open-Label, Multicenter Study of Amivantamab in Addition to Carboplatin and Pembrolizumab, Compared to Standard of Care Platinum and Pembrolizumab and 5-FU, in Participants With Treatment-Naïve Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
The purpose of this study is to compare anti-tumor activity of amivantamab in addition to pembrolizumab and carboplatin versus pembrolizumab, 5-fluorouracil (FU), and platinum therapy (carboplatin or cisplatin) in participants with refractory/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). HNSCC is a type of cancer that develops in the head and neck regions, including the outer tissue layer of the mouth and throat. This study will focus on participants with HNSCC who are treatment-naive (have not received prior treatment) in the R/M setting.
Inclusion criteria:
Exclusion criteria:
Participate-In-This-Study1@its.jnj.com844-434-4210
Miami, Florida 33136, United States
Orlando, Florida 32804, United States
Chicago, Illinois 60607, United States
Mineola, New York 11501, United States
New York, New York 10016, United States
Oberwart, A-7400, Austria
São José do Rio Preto, 15090-0000, Brazil
Vitória, 29043 260, Brazil
Wuhan, 430048, China
Sunto Gun, 411 8777, Japan
Gliwice, 44-102, Poland
Lodz, 93-513, Poland
Warsaw, 02-781, Poland
Portimão, 8500-338, Portugal
Greater London, SE1 9RT, United Kingdom